The 18 S 7y-macroglobulins (y1m-or 832M-globulins) are antibody containing molecules which are present normally in all animal species that have been appropriately examined. In man, the 'y,-macroglobulins constitute about 7% of the total gamma globulin group and 1 to 2% of all serum protein. They differ from the more abundant 6.6 S y-globulins in being larger (mol wt about 1,000,000), in being unable to pass the placental barrier, and in having distinctive antigenic characteristics (1, 2) . Antibodies such as the isohemagglutinins, typhoid 0 antibodies, and cold agglutinins are predominantly in the y,-macroglobulin group. Infants respond principally with macroglobulin antibodies (3) (4) (5) , and in adult animals and man the response to many (perhaps all) antigens normally passes through an early stage in which antibody activity is entirely limited to the 'yi-macroglobulins (6) (7) (8) (9) .
The amount of gamma macroglobulin (and macroglobulin antibody) in the serum depends on the rate and duration of macroglobulin synthesis and on the rate of y1-macroglobulin removal and catabolism.
Previous studies in animals (9, 10) and man (11) (12) (13) (14) have indicated that y1-macroglobulins are catabolized more rapidly than 6.6 S y-globulins. Half-times of 2 to 3 days have been reported for normal human gamma macroglobulin (11) , and half-times of 6.5 to 13 days have been found with macroglobulins obtained from patients with Waldenstrom's macroglobulinemia (12, 13) . In some of these studies (11) , the methods used for isolating the 71-macroglobulin may have altered the protein and thus shortened the apparent survival. In other studies (12) where radioactive labeled amino acids were used in vivo, the apparent survival may have been spuriously prolonged due to persistent radioactivity in the precursor amino * Submitted for publication October 25, 1963 ; accepted January 22, 1964. acid pool. In none of the previous studies was it possible to calculate the rate of normal y1-macroglobulin synthesis.
The present studies of normal 71-macroglobulin metabolism were undertaken when improved physicochemical methods made it possible to prepare purified and apparently unaltered normal 18 S y,-macroglobulin for turnover studies. The turnover of normal 71-macroglobulin was studied in normal subjects and in a variety of patients with diseases of the immunoglobulins. These included patients with congenital deficiency of 18 S y,-macroglobulin (agammaglobulinemia), patients with acquired deficiency (multiple myeloma, chronic lymphocytic leukemia), patients with protein-losing gastroenteropathy, and patients with excessive quantities of serum macroglobulin (Waldenstr6m's macroglobulinemia). The turnover of the patient's own anomalous macroglobulin was compared with that of normal y1-macroglobulin in three cases. As a result of these observations, some of the factors affecting y1-macroglobulin synthesis and catabolism were defined and differences noted between the metabolic behavior of 71-macroglobulins and 6.6 S y-globulins.
Methods
Patients. Seven subjects without disease of the lymphocyte-plasma cell system, four with protein-losing enteropathy, four with severe hypogammaglobulinemia, five with multiple myeloma, eight with macroglobulinemia, and five with other diseases were studied. The pertinent clinical data are shown in Table I .
Of the four patients with protein-losing enteropathy, three were associated with intestinal lymphangiectasia (N.B., J.T., and L.H.) as shown by intestinal biopsies with a Crosby capsule. The fourth (M.R.) was an 8-year-old boy with an allergy to milk manifest by malabsorption and gastrointestinal protein loss. All four patients had been shown to have accelerated 1P"1 albumin turnover, and gastrointestinal protein loss was confirmed by I.3. polyvinylpyrrolidine and chromium"-albumin studies.
The group with marked hypogammaglobulinemia in-1036 Two patients (F.C. and K.I.) had received plasmapheresis therapy of 12 and 2 months duration, respectively, and required removal of 4 U of plasma per week, but plasmapheresis was discontinued during the study period.
The five other patients studied included two with idiopathic nephrosis, one with chronic lymphocytic leukemia, one with a malignant lymphoma, and one with hypergammaglobulinemia due to an anomalous protein with a sedimentation value of 14 S.
All patients studied were considered suitable for turnover studies. None of the patients was critically ill during the study period. All patients maintained body weight and their normal dietary intake during the study. Adequate urinary and fecal collections were possible in all cases.
Preparation of labeled y1-macroglobldin. Two separate studies were performed with radioiodine-labeled normal 71-macroglobulin. For each study normal -y,-macroglobulin was prepared from freshly obtained serum of a healthy normal donor. In addition, three patients with macroglobulinemia received radioiodine-labeled preparations of their own macroglobulin. All reagents were prepared with sterile pyrogen-free water, and all equipment was autoclaved. The fractionation procedure has been described in detail previously (15) . The modification employed here will be described briefly.
Twenty ml of fresh serum was concentrated twice by ultrafiltration and applied to a block composed of 240 g of polyvinyl chloride particles 1 and 240 g of polyvinyl chloride-polyvinyl acetate copolymer 2 in sodium barbiturate buffer pH 8.6. After electrophoresis at + 6°C for 18 hours the section of the block containing the gamma globulin was removed, the proteins were eluted with saline, concentrated to 2 ml by ultrafiltration, and dialyzed against 1.0 M NaCl, 0.1 M Tris buffer pH 8. The electrophoretically prepared gamma globulin fraction was then applied to a column of Sephadex G-200 3 equilibrated with the pH 8 Tris NaCl buffer. Two major protein peaks were recovered in the effluent. The first fraction contained the 18 S gamma macroglobulin, and the second contained 6.6 S y-globulin and a small amount of /32A-globulin. Only the first fraction was used for I131_ labeling. Before iodination, samples of the two preparations of normal gamma macroglobulin were tested by immunoelectrophoresis, and one by ultracentrifugation and found to contain only 18 S y,-macroglobulin. The anomalous gamma macroglobulins of three patients with Waldenstr6m's macroglobulinemia were isolated and prepared in the same manner as described above.
The macroglobulins were labeled with 13. by the iodine monochloride method of McFarlane (16 globulin by self-irradiation, and the mixture was sterilized by filtration. The products were calculated to have less than 1 mole of I... per mole of macroglobulin, and 96 to 100%o of the radioactivity was precipitable with trichloroacetic acid. Throughout the preparation, labeling, and storage, the -y,-macroglobulin remained in the soluble state and the protein solutions were not frozen.
The radioiodinated protein was characterized by paper electrophoresis and Sephadex G-200 filtration (Figure 1) . A sample of the I"' gamma macroglobulin preparation was added to normal serum, and the mixture was examined by paper electrophoresis. Analysis of the paper strip for radioactivity with a continuously recording counting rate meter, equipped with an endwindow Geiger-Mueller tube, showed that radioactivity was present in the faster half of the gamma globulin region (i.e., the normal y-macroglobulin region). When the I131 y,-macroglobulin containing serum was applied to a G-200 Sephadex column, the radioactivity was limited to the initial effluent peak, i.e., the fraction containing the 18 S macroglobulins ( Figure 1 ).
Study protocol and calculation. of data. Each patient received 0.5 ml of Lugol's solution three times daily before and during the entire study period to prevent thyroidal uptake of the released I13". Approximately 20 to 25 Aic (0.2 to 0.3 mg) of I"31 y,-macroglobulin was injected intravenously from a calibrated syringe, and serum samples were obtained at 10 minutes, 20 minutes, 4 hours, 8 hours, 16 hours, 24 hours, and daily thereafter. Urine was collected in 24-hour pools throughout the entire study, and feces were examined for radioactivity in 24-, 48-, or 72-hour lots. Serum and urine samples were counted with an appropriate standard in an automatic gamma-ray well-type scintillation counter (employing a thallium-activated sodium iodide crystal). Stools were collected in paint cans, brought to a constant volume, and shaken in a paint can shaker. The homogenized samples were counted in a gamma-ray scintillation counter.
The data were analyzed according to the method of Berson, Yalow, Schreiber, and Post (17) . Plots were constructed on semilogarithmic paper of the serum radioactivity and of the remaining whole body activity as plotted against time. Whole body activity was calculated by cumulative subtraction of radioactivity excreted in urine and stool from that originally administered. After initial equilibration, the two curves each declined as a single exponential function, each having a comparable slope. The biological half-life (tj) was calculated from these curves. With the ti, the fraction of the total body -y,-macroglobulin catabolized per day could be determined. Fraction of the total body -y,-macroglobulin catabolized per day = 0.693/survival tj (days).
The fractional catabolic rate was also expressed as the fraction of the intravascular pool catabolized per day. Fraction of the intravascular pool catabolized per day= daily urinary radioactivity/mean intravascular radioactivitv during that day. body -y,-macroglobulin (milligrams) X fraction of the total body -y,-macroglobulin catabolized per day/body weight (kilograms).
Total serum proteins were determined by the biuret method, and serum paper electrophoresis was performed by methods previously described (18 (19) . Gamma macroglobulin levels in patients with macroglobulinemia were determined by paper electrophoresis. The data were analyzed and compared using the significance of the difference of the means.
Results
Two preparations of 1"31-labeled normal 18 S 71-macroglobulin were injected into three and four control subjects in separate studies. The metabolic behavior of these two preparations was similar in the control subjects and in four patients who received both 71-macroglobulin preparations. Therefore, the data obtained in the two studies have been combined. A total of 37 observations was made in 33 patients (Table II) .
Control subjects. Intravenously injected I131_ The biological half-time in seven control subjects averaged 5.1 days with a range of 3. albumin (20) were studied to determine the fate of the y1-macroglobulins in the presence of protein-losing gastroenteropathy. The serum yi-macroglobulin levels were subnormal in three patients (27 to 32 mg per 100 ml) and at the lower range in the fourth.
The survival of I131-labeled yl-macroglobulin was shorter in this group of patients than in any other group studied (Figure 2 ). The mean tX was 1.4 days with a range of 1.0 to 1.7 days. A typical study is shown in Figure 3 . Calculation of the y1-macroglobulin turnover rates (Table II) , however, revealed that the y1-macroglobulin synthetic rate was in the normal range (i.e., 4 to 12 mg per kg per day). Thus, there was no evidence that these patients had any compensatory increase in y1-macroglobulin synthesis to counterbalance the rapid loss. These observations suggest that y,-macroglobulins are among the proteins lost into the gastrointestinal lumen in this disease, where digestion presumably occurs.
In the nephrotic syndrome, the smaller serum proteins are lost preferentially, and macroglobulins are lost into the urine only with severe renal damage (21) . The fate of labeled yl-macroglobulin was studied in two patients with the nephrotic syndrome (patients S.L. and B.G. under Others in Tables I and II) . Although urinary protein losses were 4 and 1 g per day, in neither case was trichloroacetic acid-precipitable radioactivity found in the urine, evidence that y1-macroglobulin was not being lost via the kidney. In one case the serum -y,-macroglobulin level was normal and in the other it was high, and a corresponding normal or increased turnover (synthetic) rate was found (Table II) . The /1-macroglobulin halftimes were normal (tj = 4.9 and 4.0 days, respectively). In these two nephrotic patients, renal loss of other proteins and hypoproteinemia did not alter y,-macroglobulin catabolism.
Agammaglobulinemia. Four patients with severe hypogammaglobulinemia all had markedly depressed serum -y1-macroglobulin levels (6 to 12 mg per 100 ml). Despite the low serum levels, there was no evidence of prolonged y1-macroglobulin survival. The average t4 for the group was 4.3 days with a range of 2.2 to 6.5 days ( Figure  2 Figure  4 ) and accelerated catabolism in the latter (Figure 2) . Multiple myeloma. Low serum 71-macroglobulin levels were found in five patients with multiple myeloma (the levels being 10 to 28%o of the mean control value). The finding of reduced Ylmacroglobulin levels in one patient with a P2A-myeloma protein, as well as in four with -y-myeloma proteins, is representative of the experience in a larger group of patients with multiple myeloma (22 in the macroglobulinemic patients ranged from 4.6 to 8.6 days (average, 5.9 days). This does not differ significantly from the control group data (t = 1.69; p = 0.10 to 0.20).
The turnover of y1-macroglobulin calculated in Table II than that found for the normal y,-macroglobulin.
The tj of 9.6 days observed in patient R.W. using his own gamma macroglobulin was appreciably longer than that found for any other macroglobulin preparation in the macroglobulinemic patients (Tables II and III) . Whether these differences noted in the catabolism of normal and anomalous gamma macroglobulins in R.W. and E.C. represent an intrinsic feature of their macroglobulins or were due to a difference occurring during the preparation or labeling of the proteins remains unexplained. Although these differences were noted, the data relating the normal and anomalous macroglobulins were sufficiently comparable to warrant the assumption that the estimated synthetic rates of y,-macroglobulins in these patients (Tables II and IV) (24) . In contrast, the smaller serum proteins such as albumin (mol wt, 69,000), 6.6 S y-globulin (160,000), and transferrin (90,000) are approximately 40 to 50% intravascular (11, 17, (25) (26) .
I131-labeled normal .y-macroglobulin has a survival tj of about 5 days in contrast to 23 days for normal 6.6 S y-globulin (11, 25) . This observation means that about 14%o of the total body macroglobulin is catabolized and replaced each day, while only 3% of the 6.6 S y-globulin is replaced per day. Because of this and because of the difference in distribution, the serum levels of 7-i macroglobulin (0.1 g per 100 ml) and 6.6 S y-globulin (1.2 g per 100 ml) do not accurately reflect their relative rates of synthesis. The serum levels of 18 S y-macroglobulin are only 5 to 10%o of the 6.6 S y-globulin level, but the quantity of macroglobulin synthesized is 15 to 20% of the amount of 6.6 S y-globulin.
Turnover data for the proteins presumably apply to specific antibody as well. The rapid turnover of 71-macroglobulin indicates that newly formed macroglobulin antibodies would be available for a shorter time than 6.6 S y-globulin antibodies. At the same time, the 18 S antibodies would be predominantly located in the intravascular space while the smaller 6.6 S antibodies distribute themselves more widely. Since macroglobulin antibodies are formed first in response to antigen administration (7, 9) , intravascular retention of antibodies may have some significance in the early phase of the immune response. Later, with formation of 6.6 S antibodies, the large antibodies may no longer be needed or may even be deleterious, so that their rapid removal would be of value. Further work is needed, however, to determine the roles of macroglobulin and 6.6 S ,-globulin antibodies in the immune response.
The survival of I131 y-macroglobulin in the present study appeared to be independent of the serum concentration or total body pool of y-macroglobulin. The 7y-macroglobulin survival (t4) was essentially the same in the normal controls as in the patients with markedly reduced 7y-macroglobulin levels (agammaglobulinemia) and markedly increased levels (macroglobulinemia). Gamma macroglobulin degradation took place by a first order process with a constant fraction of the body 71-macroglobulin pool being degraded over a wide range of serum concentrations. The survival of ceruloplasmin (27) and fibrinogen (28, 29) has also been shown to be independent of the serum concentration. On the other hand, a direct relationship between the fractional catabolic rate and the serum concentration has been found for 6.6 S -y-globulin (25, 30) and possibly for albumin (31, 32) . The fractional catabolic rate of 6.6 S y-globulin is increased in most subjects with an elevated 6.6 S y-globulin concentration due to chronic infection (33), hyperimmunization (30) , or multiple myeloma with y-myeloma proteins (25, 34, 35) . In contrast, 6.6 S y-globulin catabolic rate is normal or decreased in patients with agammaglobulinemia or macroglobulinemia where the levels of 6.6 S y-globulin are reduced (25, 36) . The present observations confirm and extend previous observations (25, 30 ) that 6.6 S y-globulins and 18 S y1-macroglobulins are catabolized by separate processes.
Evidence for a role of bacterial environment in stimulating total gamma globulin synthesis has been found in studies with germ-free animals (37 18 .7%o per day, is assumed to be due to loss into the gastrointestinal tract, it can be calculated that an average protein equivalent of about 40% of the intravascular pool of 7y-macroglobulin was lost in this manner each day. All four of the patients with protein-losing enteropathy had previously been studied with 1131 albumin, and two of these had also had I131 6.6 S gamma globulin turnover studies. In these patients the increase in catabolism (above the normal) for albumin, 6.6 S y-globulin, and 18 S yl-macroglobulin was similar (35 to 40%o of the intravascular pool). The finding that plasma proteins of different size are lost at similar rates in gastroenteropathy contrasts with the urinary protein losses in nephrotic syndrome where size determines the relative amount lost as shown by Blainey, Brewer, Hardwicke, and Soothill (21) . The findings in patients with gastrointestinal protein loss are compatible with transmission of plasma itself, or a substance closely related to plasma, into the gastrointestinal tract in quantities that may be equivalent to more than one-third of the total plasma volume per day.
Summary
The metabolic behavior of normal human Ylmacroglobulin was studied in seven normal subjects and in 26 patients with a variety of diseases. y1-Macroglobulins were isolated from normal human serum, labeled with 1131, and utilized in 37 turnover studies in 33 subjects. The relative roles of synthesis and catabolism in determining serum y1-macroglobulin levels were assessed.
The yl-macroglobulins remained predominantly in the intravascular compartment with an average value of 82%o for the whole group. This is similar to observations on the distribution of fibrinogen (80%o intravascular) but differs from 6.6 S y-globulins, albumin, and transferrin where only about 40% of the body content is intravascular.
The biological half-time (ti) of yl-macroglobulin was found to average 5.1 days in the control subjects. Approximately 18%o of the circulating Y7-macroglobulin was catabolized per day. In the control subjects the turnover (synthetic) rate of y1-macroglobulin was found to be 0.2 to 0.7 g per day, averaging 6.9 mg per kg per day.
yf-Macroglobulin metabolism differs from 6.6 S gamma globulin metabolism in the shorter survival of y1-macroglobulin (5.1 vs. 23 days) and in the lower net synthetic rate (15 to 20% of the amount of 6.6 S gamma globulin synthesized per day).
Low serum y1-macroglobulin levels were found in agammaglobulinemia. multiple myeloma, and protein-losing gastroenteropathy. In agammaglobulinemia and multiple myeloma, deficient Ymacroglobulin synthesis was responsible for low serum levels.
In protein-losing gastroenteropathy, increased catabolism (ti averaged 1.5 days) was responsible for the low serum y1-miacroglobulin levels. The rate of y1-macroglobulin synthesis was normal, however, indicating that no compensatory increase in y,-macroglobulin synthesis had occurred in the patients with protein-losing gastroenteropathy.
In macroglobulinemia the high serum macroglobulin level was due to markedly increased synthesis of the anomalous macroglobulin. d-Penicillamine had no effect on the rate of yl-macroglobulin catabolism in two patients.
Observations were made in patients with serum yi-macroglobulin levels ranging from 5 to 5,0007%
of normal. These indicate that the serum yl-macroglobulin level is directly related to the rate of y1-macroglobulin synthesis (in the absence of abnormal gastrointestinal protein loss) and that there is no relationship between the fractional catabolic rate and the serum concentration.
